Costs of seasonal influenza vaccination in South Africa.
South Africa
cost analysis
health care economics
influenza vaccine
preventive health programmes
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
04
03
2022
accepted:
13
03
2022
pubmed:
1
4
2022
medline:
4
8
2022
entrez:
31
3
2022
Statut:
ppublish
Résumé
Influenza accounts for a substantial number of deaths and hospitalisations annually in South Africa. To address this disease burden, the South African National Department of Health introduced a trivalent inactivated influenza vaccination programme in 2010. We adapted and populated the WHO Seasonal Influenza Immunization Costing Tool (WHO SIICT) with country-specific data to estimate the cost of the influenza vaccination programme in South Africa. Data were obtained through key-informant interviews at different levels of the health system and through a review of existing secondary data sources. Costs were estimated from a public provider perspective and expressed in 2018 prices. We conducted scenario analyses to assess the impact of different levels of programme expansion and the use of quadrivalent vaccines on total programme costs. Total financial and economic costs were estimated at approximately USD 2.93 million and USD 7.91 million, respectively, while financial and economic cost per person immunised was estimated at USD 3.29 and USD 8.88, respectively. Expanding the programme by 5% and 10% increased economic cost per person immunised to USD 9.36 and USD 9.52 in the two scenarios, respectively. Finally, replacing trivalent inactivated influenza vaccine (TIV) with quadrivalent vaccine increased financial and economic costs to USD 4.89 and USD 10.48 per person immunised, respectively. We adapted the WHO SIICT and provide estimates of the total costs of the seasonal influenza vaccination programme in South Africa. These estimates provide a basis for planning future programme expansion and may serve as inputs for cost-effectiveness analyses of seasonal influenza vaccination programmes.
Sections du résumé
BACKGROUND
Influenza accounts for a substantial number of deaths and hospitalisations annually in South Africa. To address this disease burden, the South African National Department of Health introduced a trivalent inactivated influenza vaccination programme in 2010.
METHODS
We adapted and populated the WHO Seasonal Influenza Immunization Costing Tool (WHO SIICT) with country-specific data to estimate the cost of the influenza vaccination programme in South Africa. Data were obtained through key-informant interviews at different levels of the health system and through a review of existing secondary data sources. Costs were estimated from a public provider perspective and expressed in 2018 prices. We conducted scenario analyses to assess the impact of different levels of programme expansion and the use of quadrivalent vaccines on total programme costs.
RESULTS
Total financial and economic costs were estimated at approximately USD 2.93 million and USD 7.91 million, respectively, while financial and economic cost per person immunised was estimated at USD 3.29 and USD 8.88, respectively. Expanding the programme by 5% and 10% increased economic cost per person immunised to USD 9.36 and USD 9.52 in the two scenarios, respectively. Finally, replacing trivalent inactivated influenza vaccine (TIV) with quadrivalent vaccine increased financial and economic costs to USD 4.89 and USD 10.48 per person immunised, respectively.
CONCLUSION
We adapted the WHO SIICT and provide estimates of the total costs of the seasonal influenza vaccination programme in South Africa. These estimates provide a basis for planning future programme expansion and may serve as inputs for cost-effectiveness analyses of seasonal influenza vaccination programmes.
Identifiants
pubmed: 35355414
doi: 10.1111/irv.12987
pmc: PMC9343325
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
873-880Subventions
Organisme : NCEZID CDC HHS
ID : U50 CK000431
Pays : United States
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© 2022 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Références
Wkly Epidemiol Rec. 2012 Nov 23;87(47):461-76
pubmed: 23210147
Vaccine. 2018 Feb 8;36(7):997-1007
pubmed: 29373192
Vaccine. 2013 Nov 4;31(46):5339-48
pubmed: 24055351
BMC Med. 2022 Mar 8;20(1):88
pubmed: 35255920
Influenza Other Respir Viruses. 2022 Sep;16(5):873-880
pubmed: 35355414
Value Health. 2019 Oct;22(10):1146-1153
pubmed: 31563257
Influenza Other Respir Viruses. 2018 Jan;12(1):13-21
pubmed: 29143498
Influenza Other Respir Viruses. 2019 Sep;13(5):484-495
pubmed: 31187609
Clin Infect Dis. 2019 Aug 30;69(6):1036-1048
pubmed: 30508065
Hum Vaccin. 2010 Mar 21;6(3):
pubmed: 20009517
BMJ Open. 2020 Aug 20;10(8):e035578
pubmed: 32819939
Vaccine. 2019 Jan 3;37(1):25-33
pubmed: 30471956
Open Forum Infect Dis. 2017 Feb 10;4(1):ofw262
pubmed: 28480255
PLoS Med. 2017 Dec 12;14(12):e1002468
pubmed: 29232366
Open Forum Infect Dis. 2019 Mar 19;6(3):ofz020
pubmed: 30906797
Vaccine. 2012 Sep 7;30 Suppl 3:C79-86
pubmed: 22939027
Cochrane Database Syst Rev. 2018 Feb 01;2:CD004876
pubmed: 29388197
Vaccine. 2018 Jun 27;36(28):3993-3997
pubmed: 29866617
Vaccine. 2014 Apr 7;32(17):1954-63
pubmed: 24530145
Hum Vaccin Immunother. 2016 Oct 2;12(10):2712-2717
pubmed: 27435025
Euro Surveill. 2021 Jul;26(29):
pubmed: 34296675
PLoS One. 2019 Feb 26;14(2):e0210497
pubmed: 30807573
Vaccine. 2020 Jan 10;38(2):220-227
pubmed: 31669063
Afr J AIDS Res. 2016;15(1):67-75
pubmed: 27002359
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
PLoS One. 2017 Dec 27;12(12):e0190006
pubmed: 29281710
Vaccine. 2016 Oct 26;34(45):5400-5405
pubmed: 27646030
Vaccine. 2020 Jun 2;38(27):4288-4297
pubmed: 32389494
Hum Vaccin Immunother. 2013 Jul;9(7):1500-11
pubmed: 23732900
Influenza Other Respir Viruses. 2018 Mar;12(2):211-219
pubmed: 29024434
Vaccine. 2021 Jan 8;39(2):412-422
pubmed: 33272702